-DOCSTART- -X- O
To -X- _ O
investigate -X- _ O
the -X- _ O
potential -X- _ O
of -X- _ O
adeno-associated -X- _ B-Intervention
viruses -X- _ I-Intervention
serotype -X- _ I-Intervention
2 -X- _ I-Intervention
( -X- _ I-Intervention
AAV2 -X- _ I-Intervention
) -X- _ I-Intervention
-mediated -X- _ I-Intervention
RNA -X- _ I-Intervention
interference -X- _ I-Intervention
( -X- _ I-Intervention
RNAi -X- _ I-Intervention
) -X- _ I-Intervention
as -X- _ O
an -X- _ O
antiviral -X- _ O
agent -X- _ O
against -X- _ O
rabies -X- _ B-Patient
, -X- _ O
recombinant -X- _ O
AAV2 -X- _ O
vectors -X- _ O
expressing -X- _ O
siRNA -X- _ O
targeting -X- _ O
the -X- _ O
nucleoprotein -X- _ O
( -X- _ O
N -X- _ O
) -X- _ O
gene -X- _ O
of -X- _ O
rabies -X- _ O
virus -X- _ O
( -X- _ O
RABV -X- _ O
) -X- _ O
( -X- _ O
rAAV-N796 -X- _ O
) -X- _ O
were -X- _ O
constructed -X- _ O
and -X- _ O
evaluated. -X- _ O
When -X- _ B-Outcome
NA -X- _ I-Outcome
cells -X- _ I-Outcome
pretreated -X- _ I-Outcome
with -X- _ I-Outcome
rAAV-N796 -X- _ I-Outcome
were -X- _ I-Outcome
challenged -X- _ I-Outcome
with -X- _ I-Outcome
RABV -X- _ I-Outcome
, -X- _ I-Outcome
there -X- _ I-Outcome
was -X- _ I-Outcome
a -X- _ I-Outcome
37.8 -X- _ I-Outcome
± -X- _ I-Outcome
3.4 -X- _ I-Outcome
% -X- _ I-Outcome
to -X- _ I-Outcome
55.1 -X- _ I-Outcome
± -X- _ I-Outcome
5.3 -X- _ I-Outcome
% -X- _ I-Outcome
reduction -X- _ I-Outcome
in -X- _ I-Outcome
RABV -X- _ I-Outcome
virus -X- _ I-Outcome
titer. -X- _ I-Outcome
When -X- _ I-Outcome
cells -X- _ I-Outcome
pre-challenged -X- _ I-Outcome
with -X- _ I-Outcome
RABV -X- _ I-Outcome
were -X- _ I-Outcome
treated -X- _ I-Outcome
with -X- _ I-Outcome
rAAV-N796 -X- _ I-Outcome
, -X- _ I-Outcome
there -X- _ I-Outcome
was -X- _ I-Outcome
a -X- _ I-Outcome
4.4 -X- _ I-Outcome
± -X- _ I-Outcome
1.4 -X- _ I-Outcome
to -X- _ I-Outcome
28.8 -X- _ I-Outcome
± -X- _ I-Outcome
3.2 -X- _ I-Outcome
% -X- _ I-Outcome
reduction -X- _ I-Outcome
in -X- _ I-Outcome
RABV -X- _ I-Outcome
virus -X- _ I-Outcome
titer. -X- _ I-Outcome
Relative -X- _ O
quantification -X- _ O
of -X- _ O
RABV -X- _ O
transcripts -X- _ O
using -X- _ O
real-time -X- _ O
PCR -X- _ O
and -X- _ O
Western -X- _ O
blot -X- _ O
revealed -X- _ O
that -X- _ O
the -X- _ O
knockdown -X- _ O
of -X- _ O
RABV-N -X- _ O
gene -X- _ O
transcripts -X- _ O
was -X- _ O
based -X- _ O
on -X- _ O
the -X- _ O
rAAV-N796 -X- _ O
inoculation -X- _ O
titer. -X- _ O
When -X- _ O
any -X- _ O
NA -X- _ B-Outcome
cells -X- _ I-Outcome
were -X- _ I-Outcome
treated -X- _ I-Outcome
with -X- _ I-Outcome
rAAV-N796 -X- _ I-Outcome
before -X- _ I-Outcome
or -X- _ I-Outcome
after -X- _ I-Outcome
challenged -X- _ I-Outcome
with -X- _ I-Outcome
RABV -X- _ I-Outcome
, -X- _ I-Outcome
significant -X- _ I-Outcome
reduction -X- _ I-Outcome
in -X- _ I-Outcome
virus -X- _ I-Outcome
titer -X- _ I-Outcome
was -X- _ I-Outcome
observed -X- _ I-Outcome
in -X- _ I-Outcome
both -X- _ I-Outcome
administrations. -X- _ I-Outcome
Mice -X- _ B-Patient
treated -X- _ B-Outcome
intracerebrally -X- _ I-Outcome
with -X- _ I-Outcome
rAAV-N796 -X- _ I-Outcome
exhibited -X- _ I-Outcome
50 -X- _ I-Outcome
± -X- _ I-Outcome
5.3 -X- _ I-Outcome
and -X- _ I-Outcome
62.5 -X- _ I-Outcome
± -X- _ I-Outcome
4.7 -X- _ I-Outcome
% -X- _ I-Outcome
protection -X- _ I-Outcome
when -X- _ I-Outcome
challenged -X- _ I-Outcome
intracerebrally -X- _ I-Outcome
or -X- _ I-Outcome
intramuscally -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
lethal -X- _ I-Outcome
RABV. -X- _ I-Outcome
When -X- _ I-Outcome
mice -X- _ I-Outcome
treated -X- _ I-Outcome
intramuscularly -X- _ I-Outcome
with -X- _ I-Outcome
rAAV-N796 -X- _ I-Outcome
were -X- _ I-Outcome
challenged -X- _ I-Outcome
intramuscularly -X- _ I-Outcome
with -X- _ I-Outcome
lethal -X- _ I-Outcome
RABV -X- _ I-Outcome
, -X- _ I-Outcome
they -X- _ I-Outcome
exhibited -X- _ I-Outcome
37.5 -X- _ I-Outcome
± -X- _ I-Outcome
3.7 -X- _ I-Outcome
% -X- _ I-Outcome
protection. -X- _ I-Outcome
When -X- _ I-Outcome
mice -X- _ I-Outcome
were -X- _ I-Outcome
intracerebrally -X- _ I-Outcome
and -X- _ I-Outcome
intramuscularly -X- _ I-Outcome
with -X- _ I-Outcome
rAAV-N796 -X- _ I-Outcome
24 -X- _ I-Outcome
hr -X- _ I-Outcome
after -X- _ I-Outcome
exposure -X- _ I-Outcome
to -X- _ I-Outcome
RABV -X- _ I-Outcome
infection -X- _ I-Outcome
, -X- _ I-Outcome
they -X- _ I-Outcome
exhibited -X- _ I-Outcome
25 -X- _ I-Outcome
± -X- _ I-Outcome
4.1 -X- _ I-Outcome
% -X- _ I-Outcome
protection -X- _ I-Outcome
The -X- _ I-Outcome
N -X- _ I-Outcome
gene -X- _ I-Outcome
mRNA -X- _ I-Outcome
levels -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
brains -X- _ I-Outcome
of -X- _ I-Outcome
challenged -X- _ I-Outcome
mice -X- _ I-Outcome
with -X- _ I-Outcome
three -X- _ I-Outcome
different -X- _ I-Outcome
administrations -X- _ I-Outcome
were -X- _ I-Outcome
reduced -X- _ I-Outcome
( -X- _ I-Outcome
55 -X- _ I-Outcome
, -X- _ I-Outcome
68 -X- _ I-Outcome
, -X- _ I-Outcome
32 -X- _ I-Outcome
and -X- _ I-Outcome
25 -X- _ I-Outcome
% -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
These -X- _ O
results -X- _ O
indicated -X- _ O
that -X- _ O
AAV2 -X- _ O
vector-mediated -X- _ O
siRNA -X- _ O
delivery -X- _ O
in -X- _ O
vitro -X- _ O
in -X- _ O
NA -X- _ O
cells -X- _ O
inhibited -X- _ O
RABV -X- _ O
multiplication -X- _ O
, -X- _ O
inhibited -X- _ O
RABV -X- _ O
multiplication -X- _ O
in -X- _ O
vivo -X- _ O
in -X- _ O
the -X- _ O
mice -X- _ O
brain -X- _ O
and -X- _ O
imparted -X- _ O
partial -X- _ O
protection -X- _ O
against -X- _ O
lethal -X- _ O
rabies. -X- _ O
So -X- _ O
, -X- _ O
it -X- _ O
may -X- _ O
have -X- _ O
a -X- _ O
potential -X- _ O
to -X- _ O
be -X- _ O
used -X- _ O
as -X- _ O
an -X- _ O
alternative -X- _ O
antiviral -X- _ O
approach -X- _ O
against -X- _ O
rabies -X- _ O
. -X- _ O

